• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cancers, Vol. 12, Pages 1285: Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children
Conclusion: This represents the largest GWAS meta-analysis conducted to date associating SNPs to VTE in children and adolescents treated on childhood ALL protocols. Validation of these findings is needed and may then lead to patient stratification for VTE preventive interventions. As VTE hemostasis involves multiple pathways, a more powerful GWAS is needed to detect combination of variants associated with VTE.
Source: Cancers - May 18, 2020 Category: Cancer & Oncology Authors: Marion K. Mateos Morten Tulstrup Michael CJ Quinn Ruta Tuckuviene Glenn M. Marshall Ramneek Gupta Chelsea Mayoh Benjamin O. Wolthers Pasquale M. Barbaro Ellen Ruud Rosemary Sutton Pasi Huttunen Tamas Revesz Sonata S. Trakymiene Draga Barbaric Ulf Tedg år Tags: Article Source Type: research

Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study.
Conclusion: The patterns of increases in VTE and ischemic stroke rates among transfeminine persons are not consistent with those observed in cisgender women. These results may indicate the need for long-term vigilance in identifying vascular side effects of cross-sex estrogen. Primary Funding Source: Patient-Centered Outcomes Research Institute and Eunice Kennedy Shriver National Institute of Child Health and Human Development. PMID: 29987313 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - July 10, 2018 Category: Internal Medicine Authors: Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, Hunkeler E, Lash TL, Millman A, Quinn VP, Robinson B, Roblin D, Silverberg MJ, Safer J, Slovis J, Tangpricha V, Goodman M Tags: Ann Intern Med Source Type: research

The impact of IV alteplase on long-term patient survival: The Georgia Coverdell acute stroke registry's experience
This study assessed the impact of thrombolytic treatment by alteplase on 1-year mortality and readmission among acute ischemic stroke patients.
Source: The American Journal of Emergency Medicine - July 31, 2017 Category: Emergency Medicine Authors: Moges S. Ido, Michael R. Frankel, Ike S. Okosun, Richard B. Rothenberg Tags: Original Contribution Source Type: research

The impact of intravenous alteplase on long-term patient survival: The Georgia Coverdell acute stroke registry's experience
This study assessed the impact of thrombolytic treatment by alteplase on 1-year mortality and readmission among acute ischemic stroke patients.
Source: The American Journal of Emergency Medicine - July 31, 2017 Category: Emergency Medicine Authors: Moges S. Ido, Michael R. Frankel, Ike S. Okosun, Richard B. Rothenberg Source Type: research